14th International Conference on Complement Therapeutics

Program - Monday, June 20

Important: The program online is copyrighted to each author and should not be copied and pasted!
  • Code of conduct

    Aegean Conferences is committed to making its meetings an inclusive space for sharing ideas and knowledge. The code of conduct can be found at:https://www.aegeanconferences.org/src/App/pages/view/AegeanCodeofConduct 


    Accommodations for the conference are at the Sheraton Hotel. The Hotel is located in Ixia, Rhodes, 14.5 km from the airport.

    Arrival and Check-in 

    Attendees are expected to arrive/check-in after 3:00 PM local time. Registered participants arriving after 10:00 PM should make alternative dinner arrangements.  

    Conference Venue

    The Sheraton Conference Center is located at the hotel.  

    Handicapped Accessibility 

    The site is fully handicapped accessible. 

    Oral Presentations

    Speakers are asked to bring their USB flash drive to the reception desk at least 30 minutes prior to the session. The allocated time for all presentations, unless otherwise indicated, includes five minutes Q&A. 

    City Tour

    Buses for the city tour will depart from the hotel front lobby 3:00 PM. Badges are required for participation. 


    Breakfast for registered participants and registered accompanying persons will be served at the Sheraton Hotel main restaurant during the hours scheduled in this program.

    Lunches/Informal Discussions

    Lunches for registered participants and registered accompanying persons will be served during the times indicated in this program at the main restaurant. Badges are required for admission.

    Dinners/Informal Discussions

    Three of the dinners/informal discussions will be served during the times indicated in the program. Vegetarian entrees are available only upon request in advance of the meeting. 

    Internet, Phone, & Computer 

    Wireless internet access is available throughout the conference center free of charge during meeting hours. 

    Certificate of Participation

    A Certificate of Participation will be distributed to a participant for those sessions that the participant has attended. A participant must attend an entire session to receive credit for that particular session. Late arrivals and early departures from a session will preclude a participant from receiving credit for that session.

    Meeting Room Policy

    Mask Recommendation

    Face masks are recommended indoors.

    No Photographs and Recording Devices 

    Participants are not allowed to photograph and/or record using cameras, mobile telephones and other recording devices during the slide and poster presentations. 

    Other Information

    Animals are not permitted on site. 

    Badges are required for admission to all events. 

    All Aegean Conferences events are non-smoking. 


    Aegean Conferences expects attendees to conform their conduct at these meetings to the policies and procedures of their employing institution or company. If we learn of improper conduct by an attendee, we will take appropriate action, including reporting such conduct to the attendee's employing institution or company and barring the attendee from participation in our meetings.

    The Aegean Conferences is committed to protecting the privacy of its visitors. Information that our meeting participants provide or that is derived from internal website tracking is not sold, rented or shared with any individual or organization.  You can let us know that you would prefer not to receive information by e-mail at any time, simply by sending an e-mail to unsubscribe@aegeanconferences.org. If you do so, we will not use your personal information for informing you on our future meetings and other services. 

Monday, June 20

08:00 AM - 09:00 AM
Complement in neuroinflammation and neurodegenerative diseases
Chairs: Cynthia Ann Lemere and Paul Morgan
09:00 AM - 09:20 AM
Targeting complement for therapy of neurodegenerative diseases.
Paul Morgan
09:20 AM - 09:40 AM
Global C3 lowering in adult mice protects against hippocampal aging
Andre Batista1,2, Esra Yalcin3,4, Maren Schroeder1, Khyrul Khan1, Shaomin Li1,2, Michelle Mei1, Jessy Presumey3,4, Michael Carroll3,4, and Cynthia Lemere1,2
09:40 AM - 10:00 AM
The contribution of the terminal pathway to disease progression in neurological disorders
Frank Baas
10:00 AM - 10:15 AM
Complement inhibition facilitates lesion repair in an ex vivo model of neuromyelitis optica lesion formation
Katherine Given1, Elizabeth Acker3, and Jeffrey Bennett2
10:15 AM - 10:30 AM
ARGX-117, a therapeutic antibody targeting C2, blocks complement activation in a disease model for multifocal motor neuropathy
Inge Van de Walle1, Kevin Budding2, Lill Johansen3, Kim Dijkxhoorn2, Elisabeth de Zeeuw2, Lauri Bloemenkamp2,3,4, Domenica Gandini1, Olivier Van de Steen1, Jeanette Leusen2, Hans de Haard1, C. Hack2, and W. van der Pol4
10:30 AM - 10:45 AM
Targeting novel anti-complement drugs to the brain for therapy of dementia.
Wioleta Zelek1, Ryan Bevan1, Maarten Dewilde2, Bart De Strooper3, and Bryan Morgan1
10:45 AM - 11:30 AM
Coffee Break and Poster Viewing
Complement targeting in ocular inflammation and hemolytic disorders
Chairs: Gregory Hageman and Bärbel Rohrer
11:30 AM - 11:45 AM
AMD is Two Distinct Biological Diseases: Chromosome 1-directed Therapeutics for Future Clinical Trials and Treatment
Gregory Hageman, Chris Pappas, Jin Liu, Robert Amstadt, Brandi Williams, Nathan Seager, Jill Hageman, Karen Curtin, Moussa Zouache, and Burt Richards
11:45 AM - 12:00 PM
Elucidating the association between complement factor H-related 4 and age-related macular degeneration
Moussa Zouache, Chris Pappas, Robert Anstadt, Jin Liu, Stacie Matthews, Jill Hageman, Burt Richards, and Gregory Hageman
12:00 PM - 12:15 PM
A complement alternative pathway inhibitor delivered by gene therapy in a mouse model of RPE damage is effective only after subretinal rather than intravitreal placement.
Balasubramaniam Annamalai1, Nathaniel Parsons1, Crystal Nicholson1, Elisabeth Obert1, Bryan Jones3, and Bärbel Rohrer1,2
12:15 PM - 12:30 PM
Complement biomarker analysis from a first-in-human phase I/II gene therapy trial (FOCUS) of subretinally delivered GT005, an investigational AAV2-factor I vector, in patients with geographic atrophy secondary to age-related macular degeneration
Claire Harris, James Francis, Eva Pekle, Sonal Varsani, Emanuela Gardenal, Kate Carney, Anna Dreismann, Luisa Mendonca, Darin Curtiss, Nadia Waheed1,, and Jane Hughes
12:30 PM - 12:45 PM
Complement activation implication in Sickle Cell Disease organ injuries in patients and a mice model
Anne Grunenwald, Julie Peliconi, Margot Revel, Julien Lavergne, Elodie Voilin, V Poillerat, and Lubka Roumenina
12:45 PM - 01:15 PM
Live poster session A: 5-min flash talks
01:05 PM - 03:30 PM
Lunch and Informal Discussions
03:30 PM - 07:30 PM
City Tour and Discussions
07:30 PM - 10:30 PM
Dinner and Informal Discussions